Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J/Basilea's Ceftobiprole Faces Another Setback

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits

You may also be interested in...



FDA Panel Votes For Theravance’s Telavancin, Against Targanta’s Oritavancin

Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.

Theravance’s Telavancin Prompts Renal Concerns, But No Questions From FDA

Safety signal from trials appears in FDA’s briefing materials, but not in list of questions for the Anti-Infective Drugs Advisory Committee.

J&J/Basilea’s Ceftobiprole NDA Edges Ahead

“Approvable” word from FDA represents a victory in tough antibiotic field.

Related Content

Topics

UsernamePublicRestriction

Register

PS004002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel